Article citationsMore>>

M. J. Caslake, G. Stwart, S. P. Day, E. Daly, F. McTaggart, M. J. Chapman, P. Durrington, P. Laggner, M. Mackness, J. Pears and C. J. Packard, “Phenotype-Dependent and -Independendent Actions of Rosuvastatin on Atherogenc Lipoprotein Subfractions in Hyperlipidaemia,” Atherosclerosis, Vol. 171, No. 2, 2003, pp. 245- 253. doi:10.1016/j.atherosclerosis.2003.08.025

has been cited by the following article:

• TITLE: Rosuvastatin Reduces Plasma Small Dense Ldl-Cholesterol Predominantly in Non-Diabetic Hypercholesterolemic Patients

  AUTHORS: Gen Yoshino, Saburo Nakano, Tomoko Matsumoto, Eiichi Murakami, Toshisuke Morita, Koji Kuboki

  KEYWORDS: Rosuvastatin; Small Dense LDL-Cholesterol (sdLDL); Large Buoyant LDL-C (lbLDL-C); Apolipoprotein (apo) B; Small Dense LDL-Cholesterol (sdLDL)/Large Buoyant LDL-C (lbLDL-C) Ratio

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.3 No.1, January 12, 2012

  ABSTRACT: Aims: Small dense LDL (sdLDL) cholesterol is considered a cardiovascular risk. Our purpose in this study was to evaluate the efficacy of rosuvastatin in reducing sdLDL and large buoyant LDL (lbLDL-C) in hypercholesterolemia. Methods: Fifty-six patients with a mean baseline LDL-cholesterol (LDL-C) concentration of 173.9 ± 40.5 mg/dL were treated with rosuvastatin 2.5 mg/day for 12 weeks. LDL-C, sdLDL-C, and apolipoprotein (apo) B were assessed and l lbLDL-C was calculated (LDL-C minus sdLDL-C). Results: After 12-week treatment with rosuvastatin 2.5mg, sdLDL-C and lbLDL-C were significantly reduced from 62.1 ± 23.8 mg/dL to 34.0 ± 13.4 mg/dL, p